Ionis Pharmaceuticals (NASDAQ: IONS) was down about 13.1% at $50.51 in Tuesday premarket trade, per Yahoo Finance/Reuters — the worst single-name move on US screens this morning. The trigger isn't Ionis' own news. It's a partner's trial that ran for six years and came back with nothing.

What actually happened

On Sept 4 Novartis released topline data from Lp(a)HORIZON, the Phase 3 outcomes trial for pelacarsen — a drug Ionis discovered and licensed to Novartis in 2019. The study enrolled 8,323 high-risk cardiovascular patients. Pelacarsen did the thing it was designed to do: it lowered lipoprotein(a), the inherited cholesterol-like particle that roughly one in five people carry at elevated levels. Prior studies put that reduction around 72%.

It just didn't matter. The trial missed its primary endpoint — no statistically significant drop in the composite of cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularisation. Novartis' CMO Shreeram Aradhye put it plainly: lower Lp(a) "did not demonstrate that this translated into reduced cardiovascular risk in the overall study population."

Why Ionis fell harder than Novartis

Novartis is a ~$200bn diversified drugmaker and shed a bit over 3% on Monday. Ionis is a royalty story, and this was its biggest royalty. Under the 2019 licence Ionis was entitled to tiered royalties from the mid-teens to low-20% of net sales, plus up to $650m in development, regulatory and commercial milestones. William Blair had pegged pelacarsen's peak US sales potential at roughly $6bn a year. Canaccord took its price target from $95 to $85 on Tuesday and simply deleted pelacarsen revenue from the model — while keeping a Buy.

The ripple

The read-through hit the whole Lp(a) class. Amgen fell 4.7% to $416.88 premarket — but two separate things drove that, and they shouldn't be mashed together. One is olpasiran, Amgen's own Lp(a) drug, whose OCEAN(a)-Outcomes readout in 2028 now carries a much higher burden of proof. The other is a straight BMO downgrade to Market Perform (target held at $450) on valuation after a 34% year-to-date run, plus patent-cliff worries. Eli Lilly's lepodisiran sits in the same boat with ACCLAIM data not due until 2029. The bull counter: olpasiran cuts Lp(a) by over 95% and lepodisiran by ~94%, versus pelacarsen's ~72% — so the class may just need to hit harder.

The one thing that flips it

Ionis has told investors it still gets to cash-flow breakeven in 2028 without pelacarsen. The nearest test of that is Oct 26 — the FDA decision date for GSK's bepirovirsen in hepatitis B, another Ionis-originated asset. An approval restores a real royalty line and the "diversified pipeline" argument holds. A rejection, and a stock already down 27% year-to-date loses the story Canaccord is buying.

As of 10:10 AM ET / 7:40 PM IST, Tue 8 Sep 2026. Sources: Yahoo Finance, Novartis, Fierce Biotech, BioPharma Dive, Investing.com, BioSpace. For discussion and education only — not investment advice. Verify before acting.